top of page

GPCR News 

Post: Blog2_Post

Domain Therapeutics Raises $42m Series A Financing

May 2022


"Published: May 10, 2022

To accelerate clinical development of its best-in-class and first-in-class immuno-oncology programs STRASBOURG, France & MONTREAL- Domain Therapeutics, a biopharmaceutical company specializing in the research and development of innovative drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology, announced today the closing of a US $42m (€39m) series A financing round co-led by Panacea Venture, CTI Life Sciences and 3B Future Health Fund, and joined by adMare BioInnovations, Schroders Capital, Omnes, Turenne Capital, Theodorus, Viva BioInnovator and existing investor Seventure Partners."


Recent Posts

See All

Commentaires


Become a Member

Powered by


All Rights Reserved © 2020 - 2024

Dr. GPCR CORP is a 501(c)(3) non profit organization

  • Facebook
  • Twitter
  • LinkedIn
  • Instagram
bottom of page